Correspondence 0001104659-24-096870 from BRAINSTORM CELL THERAPEUTICS INC. (BCLI) (CIK 0001137883) (BCLI)
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) (CIK 0001137883)
Date: Sept. 4, 2024 · CIK: 0001137883 · Accession: 0001104659-24-096870
AI Filing Summary & Sentiment
File numbers found in text: 333-281827
Letter
Brainstorm Cell Therapeutics Inc.
1325 Avenue of the Americas, 28th Floor
New York, NY 10019
September 4, 2024
Via EDGAR Transmission
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Brainstorm Cell Therapeutics Inc. Acceleration Request for Registration Statement on Form S-3 (File No. 333-281827)
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Brainstorm Cell Therapeutics Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to September 6, 2024, at 4:30 pm Eastern Time, or as soon thereafter as practicable, unless we or outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
If you have any questions regarding this request, please contact Mayan Katz of Goodwin Procter LLP at (212) 459-7269.
Sincerely,
Brainstorm Cell Therapeutics Inc.
Show Raw Text
CORRESP
1
filename1.htm
Brainstorm Cell Therapeutics Inc.
1325 Avenue of the Americas, 28th
Floor
New York, NY 10019
September 4, 2024
Via EDGAR Transmission
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Brainstorm Cell Therapeutics Inc. Acceleration
Request for Registration Statement on Form S-3 (File No. 333-281827)
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities
Act of 1933, as amended (the “Act”), Brainstorm Cell Therapeutics Inc. (the “Company”) hereby requests
that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated
to September 6, 2024, at 4:30 pm Eastern Time, or as soon thereafter as practicable, unless we or outside counsel, Goodwin Procter
LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request,
the Company acknowledges that it is aware of its responsibilities under the Act.
If you have any questions regarding this request,
please contact Mayan Katz of Goodwin Procter LLP at (212) 459-7269.
Sincerely,
Brainstorm Cell Therapeutics Inc.
/s/ Chaim Lebovits
Chaim Lebovits
Chief Executive Officer and Principal Executive Officer
cc:
Mitchell S. Bloom, Esq., Goodwin Procter LLP
Mayan Katz, Esq., Goodwin Procter LLP